2020 Year in Review - Breast Cancer

Analysis from the PALOMA-3 clinical trial showed that the combination of palbociclib and fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer. Read More ›

Thrombotic event incidence was higher in this real-world study than that which was reported in clinical trials, with arterial thrombosis accounting for more than one-third of events. Read More ›

Primary analysis of a multicenter, randomized clinical trial suggests that endocrine therapy demonstrates benefits over capecitabine when used as a maintenance therapy after first-line combination chemotherapy in hormone receptor–positive, HER2-negative advanced metastatic breast cancer. Read More ›

This real-world study of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with a palbociclib-based therapy as either first- or second-line therapy, showed similar safety and efficacy when compared with clinical study results. Read More ›

During the COVID-19 pandemic, there was a decline in the number of patients beginning first-line treatment. There was a decrease in the percentage of patients receiving CDK4/6 inhibitor combination therapy while a simultaneous increase in endocrine monotherapy was observed. Read More ›

In a large, diverse cohort of patients, this analysis confirms the safety and efficacy of ribociclib plus letrozole with data that are consistent with those observed in the MONALEESA trials, supporting the use of this combination in the first-line setting. Read More ›

When combined with fulvestrant, alpelisib produced clinically and statistically relevant progression-free survival despite the baseline poorer prognosis in patients with hormone receptor–positive, HER2-negative, PIK3CA mutation–positive advanced breast cancer. Read More ›

Patients and oncologists are prepared to make trade-offs between efficacy and toxicities, but patients appreciate toxicities impacting quality of life while endeavoring to increase survival. Read More ›

In patients with metastatic hormone receptor–positive breast cancer treated previously with a CDK4/6 inhibitor, there was a lower median progression-free survival benefit from everolimus in combination with exemestane compared with those patients who had not received this combination. Read More ›

Page 1 of 4

© Amplity Health. All Rights Reserved. Privacy Policy.